Chinese Licorice Root

Glycyrrhiza uralensis delivers anti-inflammatory and hepatoprotective effects primarily through its triterpenoid saponin glycyrrhizin (~3.37% in dried root) and chalcone flavonoids including isoliquiritigenin, which suppress inducible nitric oxide synthase (iNOS) expression and NO production in hepatocytes with isoliquiritigenin achieving an IC₅₀ of 11.9 μM. The most clinically significant evidence to date derives from preclinical models, where the Nrf2-activating isoprenylated phenolic echinatin attenuated CCl₄-induced liver injury in mice at 5–10 mg/kg IP, and CYP450 modulation studies in HepG2 cells at 25–50 μM confirm meaningful pharmacokinetic interaction potential.

Origin & History

Glycyrrhiza uralensis is native to northern and northeastern China, Mongolia, and parts of Siberia, thriving in semi-arid steppe environments with well-drained, alkaline loam soils at elevations up to 1,500 meters. It has been cultivated for millennia in Chinese provinces including Gansu, Xinjiang, and Inner Mongolia, where roots are harvested from plants aged three to five years. Cultivation requires full sun and low rainfall, with wild-harvested roots historically preferred for medicinal use due to higher glycyrrhizin accumulation.

Historical & Cultural Context

Glycyrrhiza uralensis, designated Gancao (甘草, 'sweet herb') in Traditional Chinese Medicine, has been documented in Chinese materia medica texts for over 2,000 years, appearing prominently in the Shennong Bencao Jing (circa 1st century CE) as a 'superior herb' capable of harmonizing the actions of other medicinal herbs in compound formulas. It holds the distinction of being one of the most frequently prescribed herbs in the Chinese pharmacopoeia, used to regulate drug properties (jun-chen-zuo-shi system), tonify the spleen and stomach qi, moisten the lungs to relieve cough, and resolve toxicity in both food and medicinal contexts. Traditional preparation involved slow decoction of dried root slices in water, sometimes honey-roasted (Zhigancao) to amplify tonic spleen effects and reduce cold properties, with honey-roasting also being pharmacologically significant as it alters flavonoid extraction profiles. The roots were historically traded along the Silk Road, establishing G. uralensis as an early commodity herb whose sweet glycyrrhizin content (~50 times sweeter than sucrose) made it recognizable across Asian, Middle Eastern, and eventually European herbal traditions.

Health Benefits

- **Anti-inflammatory Activity**: Isoliquiritigenin and liquiritigenin suppress IL-1β-stimulated iNOS gene expression and NO production in rat hepatocytes, with isoliquiritigenin yielding the lowest IC₅₀ of 11.9 μM among all tested flavonoids, outperforming glycyrrhizin by over 98-fold in potency.
- **Hepatoprotection**: The isoprenylated phenolic echinatin activates the Nrf2 antioxidant-response pathway, reducing CCl₄-induced hepatocellular damage in mouse models at intraperitoneal doses of 5–10 mg/kg, while glycyrrhizin broadly supports liver cell integrity through anti-inflammatory and membrane-stabilizing mechanisms.
- **Respiratory and Cough Relief**: Traditional Southeast Asian and Chinese formulations employ hot-water root extracts to soothe bronchial inflammation and reduce cough reflex, with glycyrrhizin's surfactant and demulcent properties likely contributing to mucosal protection.
- **Immunomodulation**: Glycyrrhizin and associated flavonoids modulate innate immune signaling by reducing pro-inflammatory cytokine cascades initiated by IL-1β, and echinatin's Nrf2 activation supports systemic oxidative stress regulation relevant to immune homeostasis.
- **Cytotoxic and Anticancer Potential**: The isoprenylated phenolic topazolin exhibits in vitro cytotoxicity against HepG2 (hepatocellular), SW480 (colon), A549 (lung), and MCF7 (breast) cancer cell lines with IC₅₀ values ranging from 7.3 to 23.1 μM, though no clinical translation has been established.
- **CYP450-Mediated Pharmacokinetic Modulation**: Root extract constituents downregulate CYP1A2, CYP2D6, and CYP3A4 mRNA in HepG2 cells at 25–50 μM concentrations, and glycyrrhizin activates pregnane X receptor (PXR), which can modulate metabolism of co-administered drugs such as lidocaine.
- **Antioxidant Defense**: Echinatin and broader phenolic fractions from G. uralensis extracts upregulate Nrf2-dependent antioxidant genes, with in vitro data showing 72% hepatocyte viability maintained at 0.54 μM extract concentration under oxidative challenge.

How It Works

The primary anti-inflammatory mechanism operates through suppression of iNOS gene transcription and resultant reduction of nitric oxide production in IL-1β-stimulated hepatocytes; isoliquiritigenin (IC₅₀ 11.9 μM), liquiritigenin (IC₅₀ 18.5 μM), isoliquiritin (IC₅₀ 41.2 μM), and liquiritin (IC₅₀ 29.4 μM) are the principal active chalcone and flavanone contributors, while glycyrrhizin itself is comparatively weak at this target (IC₅₀ 1,176 μM). Hepatoprotection is further mediated by echinatin's activation of the Nrf2/ARE (antioxidant response element) pathway, upregulating phase II detoxification enzymes including heme oxygenase-1 and glutathione S-transferase, thereby reducing oxidative hepatocellular injury. Glycyrrhizin acts as a ligand for pregnane X receptor (PXR), inducing CYP3A expression and simultaneously inhibiting CYP2E1 activity, which reduces bioactivation of hepatotoxic substrates such as CCl₄. Over 122 characterized compounds in G. uralensis roots collectively modulate multiple nodes in inflammatory, oxidative, and xenobiotic-metabolizing cascades, producing pleiotropic pharmacological effects at physiologically relevant concentrations.

Scientific Research

The body of evidence for Glycyrrhiza uralensis consists predominantly of in vitro studies in isolated rat hepatocytes and human HepG2 hepatoma cell lines, and in vivo murine hepatotoxicity models; no published randomized controlled trials with defined sample sizes or quantified effect sizes in humans were identified in the current literature base for this specific species. Preclinical data are methodologically rigorous within their scope, with reproducible IC₅₀ values for individual flavonoids and dose-response relationships for echinatin in CCl₄ mouse models at 5–10 mg/kg IP, providing a mechanistic foundation but not direct clinical translation. Some evidence for hepatoprotective properties of glycyrrhizin (shared with G. glabra) exists in the clinical literature, but these studies are not species-specific to G. uralensis and lack sufficient reporting of effect sizes and standardization to inform dosing guidelines. Overall, the evidence base is best classified as preclinical-dominant, with compelling mechanistic plausibility but an absence of adequately powered human clinical trials specific to G. uralensis extracts.

Clinical Summary

No species-specific clinical trials for Glycyrrhiza uralensis with defined populations, control arms, and quantified human outcomes were identified in the searched literature. Preclinical hepatoprotection studies demonstrate statistically significant reduction in liver injury markers in CCl₄-challenged mice using echinatin at 5–10 mg/kg IP, and in vitro iNOS suppression is well-characterized across multiple cell models. Broader glycyrrhizin clinical data from related Glycyrrhiza species suggest hepatoprotective effects in humans, but methodological heterogeneity and lack of species-level specificity limit direct application to G. uralensis formulations. Confidence in clinical efficacy remains low pending dedicated human trials; current evidence supports biological plausibility rather than proven therapeutic outcomes.

Nutritional Profile

The dried root of Glycyrrhiza uralensis is not a significant source of macronutrients or micronutrients in typical medicinal doses but is rich in pharmacologically active phytochemicals. Glycyrrhizin (glycyrrhizic acid) constitutes approximately 3.37% of dry root weight, representing the dominant triterpenoid saponin and primary sweet principle. Quantified flavonoid concentrations in standardized extracts include isoliquiritin (~234 mg per purified fraction; 0.26 mg/mL in liquid extract), liquiritin (~8.8 mg per fraction; 0.45 mg/mL), isoliquiritin apioside (0.43 mg/mL), liquiritigenin (trace to 16.4 mg/fraction), and isoliquiritigenin (4.3 mg/fraction). Isoprenylated phenolics including echinatin and topazolin are present in minor quantities with high biological potency. Bioavailability of glycyrrhizin from oral ingestion involves intestinal hydrolysis by gut microbiota to the aglycone 18β-glycyrrhetinic acid, which is the primary systemically absorbed form; flavonoid bioavailability is enhanced by glucuronidase activity but remains variable across individuals.

Preparation & Dosage

- **Traditional Hot-Water Root Decoction**: 2–9 g of dried root per day decocted in water, consistent with Chinese Pharmacopoeia guidance for Radix Glycyrrhizae; consumed as tea or incorporated into multi-herb formulas.
- **Standardized Aqueous Extract (GR Extract)**: Prepared by hot-water extraction of roots/stolons followed by Diaion HP-20 resin fractionation yielding active fractions (GR-60, GR-80, GR-100); standardization to glycyrrhizin content (≥3% w/w by HPLC) is recommended.
- **Purified Phenolic Fractions**: Isoliquiritin-enriched fractions purified via Cosmosil C18 or Wakogel C-200 chromatography; effective in vitro concentrations range from 11.9–41.2 μM for anti-inflammatory flavonoids, with no established oral clinical dose equivalent.
- **Capsule/Tablet Supplements**: Commercially available products typically provide 300–600 mg dried root extract per dose; deglycyrrhizinated licorice (DGL) formulations remove >97% glycyrrhizin to reduce mineralocorticoid side effects but may diminish hepatoprotective glycyrrhizin-specific effects.
- **Timing**: Traditional use integrates G. uralensis as a harmonizing herb in multi-ingredient decoctions taken with or after meals; no pharmacokinetically derived optimal timing has been established for isolated extracts.
- **Standardization Note**: Products should specify glycyrrhizic acid content; the Chinese Pharmacopoeia requires ≥2.0% glycyrrhizic acid and ≥1.0% liquiritin in Radix Glycyrrhizae.

Synergy & Pairings

In traditional Chinese medicine, Glycyrrhiza uralensis is classically combined with Astragalus membranaceus (Huangqi) to synergistically tonify defensive qi and enhance immunomodulatory effects, with both herbs contributing complementary polysaccharide and saponin fractions that may additively activate macrophage and natural killer cell responses. Combination with Schisandra chinensis is employed in hepatoprotective formulas where schisandrin B and echinatin may converge on overlapping Nrf2/ARE pathway activation, potentially producing additive antioxidant enzyme induction. In respiratory blends common to Southeast Asian and East Asian traditions, G. uralensis is paired with Fritillaria thunbergii and Platycodon grandiflorum, where glycyrrhizin's surfactant and demulcent properties complement saponin-mediated expectorant effects of platycodin D, enhancing mucociliary clearance.

Safety & Interactions

At doses consistent with traditional medicinal use, Glycyrrhiza uralensis root extracts demonstrate low direct hepatocellular toxicity, with no lactate dehydrogenase (LDH) release detected in hepatocytes exposed to active flavonoid concentrations in vitro, suggesting a favorable therapeutic index at pharmacologically relevant doses. Chronic or high-dose use of non-deglycyrrhizinated preparations carries risk of pseudohyperaldosteronism due to glycyrrhizin's inhibition of 11β-hydroxysteroid dehydrogenase type 2, leading to sodium retention, hypokalemia, hypertension, and edema; the European Medicines Agency cautions against daily intake exceeding 100 mg glycyrrhizin. Significant drug interactions arise from CYP450 modulation: G. uralensis constituents inhibit CYP1A2, CYP2D6, and CYP3A4 at 25–50 μM in HepG2 cells and activate PXR-mediated CYP3A induction, creating bidirectional interaction potential with drugs including warfarin, statins, lidocaine, oral contraceptives, and corticosteroids. Contraindications include known hypertension, hypokalemia, renal insufficiency, congestive heart failure, liver cirrhosis, and pregnancy (due to potential estrogenic and cortisol-potentiating effects); lactation safety has not been established for concentrated extracts.